Synaptogenix (NASDAQ:SNPX) & Adhera Therapeutics (OTCMKTS:ATRX) Head to Head Survey

Synaptogenix (NASDAQ:SNPX) and Adhera Therapeutics (OTCMKTS:ATRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Profitability

This table compares Synaptogenix and Adhera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-42.14%	-29.42%
Adhera Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Synaptogenix and Adhera Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	0	0	1	0	3.00
Adhera Therapeutics	0	0	0	0	0.00

Synaptogenix currently has a consensus target price of $14.00, suggesting a potential upside of 382.76%. Given Synaptogenix’s stronger consensus rating and higher probable upside, research analysts clearly believe Synaptogenix is more favorable than Adhera Therapeutics.

Insider and Institutional Ownership

10.3% of Synaptogenix shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 28.2% of Adhera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Synaptogenix has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 3.1, meaning that its stock price is 210% more volatile than the S&P 500.

Valuation and Earnings

This table compares Synaptogenix and Adhera Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	N/A	N/A	-$6.04 million	N/A	N/A
Adhera Therapeutics	N/A	N/A	-$2.11 million	N/A	N/A

Summary

Adhera Therapeutics beats Synaptogenix on 5 of the 9 factors compared between the two stocks.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.